Biography: I specialize in General Surgery, working in the Greek National Health System since 1988. My main areas of interest are colonic, pelvic, hepatobiliary, gastric and thyroid surgery. I have been Director of Surgery in Surgical Department of General Hospital ''Constantopoulion - Aghia Olga'' (Athens) since 2008. I am member of numerous Medical Societies. I have participated in hundreds of Congresses, and presented my work in 160, international in their majority. I have 112 publications, 42 of them in international medical Journals. I have been trained in specific surgical topics, such as laparoscopic, thoracic and pelvic surgery (Rome, Mestre, Zurich, Berlin).
Abstract: Although acute gastrointestinal conditions are severe, processed data about rational diagnostics and therapy have not yet been sufficient, neither have relative recommendations. Polymorbidity is frequent among these patients, which along with delayed presentation and lack of available time, may often limit the possibility of using optimal therapies. Endoscopy may not result in diagnosis or may be limited by the serious general condition of patient. We discuss surgical strategies in such difficult cases.
An 88-year old man with severe comorbidities and paraesophageal hernia, hospitalized in Pathological Dept. for anaemia and dyspnea, was diagnosed with "intrathoracic stomach with pyloric stenosis" (computed tomography, gastroscopy without biopsies). He was transferred to Surgical Dept. after an acute episode of cardiorespiratory distress and chest pain. On emergent laparotomy, the entire stomach, along with omentum and spleen, were found migrated in the mediastinum. Reduction of hernia contents revealed antral ischaemia and obstructive prepyloric lesion. We performed distal gastrectomy, gastrojejunostomy, cruroraphy and fundopexy. Histology revealed a pT2 prepyloric adenocarcinoma. Postoperatively, he required support for pulmonary insufficiency and was discharged on day 28. His course is uneventful during a 19-month follow-up.
A 70-year old man with severe comorbidities and chronic constipation was admitted with complete bowel obstruction. Computed tomography indicated obstructive rectosigmoid tumour and huge dolichocolon. On emergent laparotomy, we additionally found aplastic duodenum and a palpable mass in left colonic flexure. We performed subtotal colectomy, ileostomy, mobilization of two existed duodenal portions and adhesiolysis at mesenteries. The patient was discharged on day 7. Histology revealed pT3N1b rectosigmoid adenocarcinoma and a 2 cm in diameter c-kit+ stromal tumour in the colonic flexure. He received chemotherapy and Imatinib. Bowel continuity has been restored (ileorectal anastomosis). During 13-month follow-up, no recurrence has occurred.
Gastrointestinal malignancies may incidentally be recognized during emergent surgery for other prominent acute pathology and need further treatment
Biography: Dr Bera received his M.S. and Ph.D. in Biochemistry from the Calcutta University, India and completed his postdoctoral research training at the Cancer Research Laboratory, UC Berkeley and at the Laboratory of Molecular Biology, National Cancer Institute. Dr Bera currently held the position of Senior Associate Scientist in the Molecular Biology section of the Laboratory of Molecular Biology, NCI, focusing on the development protein toxin targeting hematologic malignancies as well as discovery of new therapeutic target for prostate and breast cancer immunotherapy. Dr Bera have discovered several new and important genes whose expression is restricted to normal prostate and prostate cancer and are now being developed as therapeutic targets for the treatment of prostate cancer. He is using antibody engineering to develop a new therapy for cancer by making fusion proteins composed of the Fv portion of antibodies directed at receptor proteins on cancer cells fused to a genetically modified form of a powerful bacterial toxin, Pseudomonas exotoxin A. Dr Bera also identified a primate-specific gene family POTE that has restricted expression in normal prostate, prostate cancer and ES cells. To gain some insight on the biological function of POTE gene family, he has identified the POTE ancestor gene ANKRD26, and its mouse orthologue. To assess the function of Ankrd26, he generated a mutant mouse with partial inactivation of the Ankrd26 gene and shown that the homozygous mutant mice develop extreme obesity, insulin resistance and an increase in body size.
Abstract: Targeted therapy of cancer is getting more traction over the traditional chemotherapy to overcome the unavoidable side effects from the chemotherapeutic drugs. As scientists began to understand more about the molecular mechanism that distinguishes the cancer cells from its normal counterpart, they started to design novel approaches to attack the cancer cells more precisely. One of such successful approach is the development of monoclonal antibody against a cancer specific surface antigen that can be used as a delivery vehicle of toxic material selectively to the cancer cells. B cell maturation antigen (BCMA) is exclusively and highly expressed on normal and malignant plasma cells. Therefore, BCMA is a promising antigen for targeted therapy to treat multiple myeloma. Recombinant immunotoxins are chimeric proteins in which an Fv or Fab is fused with Pseudomonas exotoxin A (PE). We have generated a panel of monoclonal antibodies against BCMA. Two of them, BM24 and BM306, were used to make recombinant immunotoxins targeting BCMA, by genetically attaching their Fabs to a 24 kDa form of PE. The Fab immunotoxins specifically killed BCMA expressing cell lines and malignant plasma cells isolated from multiple myeloma patients. The immunotoxins are very potent and act rapidly, a 10-minute treatment of H929 cells was sufficient to kill almost all cells. Immunotoxin alone produced partial regressions of H929 tumors in mice and when combined with Abraxane produced complete and prolonged regressions.
Biography: Head of Epidemiology and Preventive Medecine Department . University Hospital of Setif , Algeria since 1984.
Director of Cancer Registry of Setif in collaboration with the International Agency for Research on Cancer (WHO), Lyon, France since 1988.
National Coordinator of Cancer Registries in Algeria
Director of Laboratory of Environment and Health in Medicine Faculty, University of Setif
President of Observatory of Tobacco Control in Francophone Africa (OTAF)
President of Ennour Association
Abstract: The National Registry Network (RNRC) was created in 2014 as part of the 2015-2019 Cancer Plan and the institutionalization of cancer registries.
The objective is to provide, for the first time, cancer incidence data for Algeria based on data from a network covering 52% of the population.
Material and method
These are the new cases recorded from 18 registers covering a population of 20 224 844, from a general population of 38 700 000 inhabitants for the year 2014. The data are entered and analyzed by the Canreg software 5, provided by IARC
The coverage of national registration rate is 82% with a 52% coverage rate of 52% at 31/12/2014.
The number of new cases during the year 2014 is 41,870 cases (16,748 men and 25,122 women). The overall crude rate is 106 / 100,000 (h), the standardized rate is 114.5 / 100,000. Crude and standardized rates in men are respectively 100.2 and 109.2 / 100,000. In women are respectively 111.8 and 119.8 / 100,000.
In men, frequent cancers are lung, colon-rectum, bladder, prostate, stomach, pharynx naso, NHL, larynx and leukemia cancers.
In women, breast cancers followed by colorectal, cervical, thyroid, NHL, stomach, biliary and leukemia cancers.
The RNRC covers half of the Algerian population with the common incidence data for research and cancer control.
Abstract: Cancer is a major health burden among non-communicable diseases and surgery in its management is essential. The incidence of urological cancers is steadily increasing in the world and will become an even more serious problem in the future. From 2000 to 2010, we proposed to study the epidemiological aspects of urological cancers operated at Yaounde Central Hospital.
We conducted a descriptive and retrospective study of the last decade in the urology department of Yaounde Central Hospital. We included patients operated for malignancies or strongly suspected of malignancy.
Ninety hundred and forty three patients were operated on for urological pathology. 223 patients (23.64%) had a malignancy or suspected malignancy. The average age in both sexes was 64.77 years. In women, it was 47.54 years old and in men 64.52 years old. The sex ratio was 5.96. In women, the most common urological malignancy was kidney tumor (38%); While in men prostate cancer dominated all other locations of tumors (86%). Surgical castration was performed in most patients with prostate cancer (95.81%).
It is necessary to set up an effective cancer registry for better patient care and anticipation of needs.
Biography: Hsiao-Sheng Liu has completed his PhD from Texas Tech University and postdoctoral studies from University of Cincinnati University School of Medicine. He was the chair of the Department of Microbiology & Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan from 2003 to 2006 and now he is the distinguished professor of National Cheng Kung University. He now focuses on Ras-induced autophagy and the role of autophagy in regulation of the oncogenic factors including microRNAs in HCC development. He is also interested in viral induced autophagy and their relationship with viral replication and viral related pathogenesis.
Abstract: Autophagy, microRNA (miRNA) and cell cycle regulator cyclin D1 are important regulators during cancer cell tumorigenesis. Low autophagic activity as well as high levels of miR-224 and cyclin D1 are prevalent in hepatocellular carcinoma (HCC) patients in Taiwan. We reveal that in hepatitis B virus (HBV)-related HCC, dysfunction of autophagy leads to accumulation of miR-224 and cyclin D1. MiR-224 decreases the expression of its target gene Smad4, which is a suppressor of cancer cell migration and tumor formation. Cyclin D1 is responsible for cell cycle pregression and cell proliferation. We disclosed that autophagosome selectively recruits both miR-224 and ubiqutinated-cyclin D1 followed by lysosome fusion and degradation using different mechanisms. Importantly, we identified an off-label use drug “amiodarone” (an antiarrhythmic agent), which effectively suppressed HCC tumorigenesis through autophagy-mediated selective degradation of miR-224 and cyclin D1 both in vitro and in vivo. In summary, for the first time amiodarone was used as an autophagy inducer to regulates two oncogenic factors of HCC simultaneously through induction of autophagic activity. Our compelling findings imply that amiodarone as a repurposing drug is a novel autophagy inducer with the potential for suppression of tumor development in HCC therapy.
Abstract: Long noncoding RNAs (LncRNAs) have been reported to be abnormally expressed in human ovarian cancer and associated with the proliferation and metastasis of cancer cells. The objective of this study was to investigate the role and the underlying mechanisms of LncRNA MAP3K20 antisense RNA 1 (MLK7-AS1) in ovarian cancer.
Methods: The expression level of MLK7-AS1 was investigated in human ovarian cancer tissues and cell lines. The effects of MLK7-AS1 knockdown on ovarian cancer cell proliferation, migration, invasion and apoptosis were evaluated in vitro using MTT, colony formation assays, wound healing assays, transwell assays and flow cytometry. Furthermore, the in vivo effects were determined using the immunocompromised NSG female mice. Luciferase reporter assays were employed to identify interactions among MLK7-AS1 and its target genes.
Results: In the current study, MLK7-AS1 was specifically upregulated in ovarian cancer tissues and cell lines. Knockdown of MLK7-AS1 inhibited the ability of cell migration, invasion, proliferation, colony formation and wound healing, whereas promoted cell apoptosis in vitro. By using online tools and mechanistic analysis, we demonstrated that MLK7-AS1 could directly bind to miR-375 and downregulate its expression. Besides, MLK7-AS1 reversed the inhibitory effect of miR-375 on the growth of ovarian cancer cells, which might be involved in the upregulation of Yes-associated protein 1 (YAP1) expression. Moreover, knockdown MLK7-AS1 expression inhibited primary tumor growth in ovaries and metastatic tumors in multiple peritoneal organs including liver and spleen in vivo, which were partly abolished by miR-375 inhibition. Mechanically, we found that MLK7-AS1 regulated the epithelial-mesenchymal transition (EMT) process by interacting with miR-375/YAP1 both in vivo and vitro, which promoted the expression of Slug.
Conclusions: Taken together, our study showed for the first time that MLK7-AS1 interacted with miR-375 to promote proliferation, metastasis, and EMT process in ovarian cancer cells through upregulating YAP1.
Abstract: To highlight the clinical association of baseline levels of conjugated dienes in low-density lipoprotein (LDL-BCD) and nitric oxide (NO) with immunoglobulins and Th1/Th2 ratio in patients with newly diagnosed B-cell non-Hodgkin’s lymphoma.
Thirty two (32) newly diagnosed patients with aggressive B-cell NHL and 25 age-, sex and body mass index (BMI)-matched healthy controls were randomly selected for a cross-sectional case-control study conducted at the Hematology Department of Tlemcen University Medical Centre (Northwest of Algeria).
Circulating levels of LDL-BCD and NO and those of IgA and IgM were significantly higher in patients than in controls. The levels of Th1/Th2 ratio and plasma total antioxidant capacity (ORAC) were significantly lower in patients compared with controls; while malondialdehyde (MDA) and protein carbonyl (PC) levels were significantly higher in patients. B-cell NHL was significantly associated with high levels of LDL-BCD from 25th to 75th percentile [25th percentile; RR = 2.26, 95% CI 1.42-3.59, p = 0.014, 50th percentile; RR = 2.84, 95% CI 1.72-4.68, p < 0.001, 75th percentile; RR = 5.43, 95% CI 2.58-11.42, p < 0.001]). Similarly, the disease was significantly associated with high levels of NO production from 25th to 75th percentile [25th percentile; RR = 2.07, 95% CI 1.25-3.44, p = 0.024, 50th percentile; RR = 2.78, 95% CI 1.63-4.72, p < 0.001, 75th percentile; RR = 4.68, 95% CI 2.21-9.91, p < 0.001]). Moreover, LDL-BCD levels were positively and significantly correlated with IFN-γ; whereas, NO levels were inversely and significantly correlated with IFN-γ and Th1/Th2 ratio.
LDL-BCD and NO production seem to be associated with aggressive B-cell NHL and alteration of Th1/Th2 ratio. Our results had to be examined using ex vivo mechanistic studies leading to further investigations among them; an interest in the link between Epstein-Barr virus infection and NO and immunoglobulins.
Biography: DR Jehad Zweiri, lecturer in Cancer studies at the University of Liverpool Medical School, born and grew up in Jordan and received his Bachelor’s degree from the University of Jordan in 1990. He obtained his master degree from London School of Hygiene and Tropical Medicine/University of London, and then obtained his PhD degree in 2000 from Kings College Medical School/University of London, in the field of Immune Gene Therapy of Cancer under the supervision of Professor Farzin Farzaneh. He then started his work as Postdoctoral Associate at the department of Immunology and Medicine at the University of Liverpool in 2002. In 2010 he was appointed as a lecturer in the University of Liverpool Medical School and he is currently fellow of the British Higher Education Academy since 2012.
Abstract: Cellular based therapeutic approaches for cancer rely on careful consideration of finding the optimal cell to execute the cellular goal of cancer treatment. Cell lines and primary cell cultures have been used in some studies to compare the in vitro and in vivo efficacy of autologous vs allogeneic tumour cell vaccines. This study examines the effect of -irradiation on a range of tumor cell lines in conjunction with suicide gene therapy of cancer. To determine the efficacy of this modality, a series of in vitro and in vivo experiments were conducted using genetically modified and unmodified tumor cell lines. Following co-culture of HSV-TK modified tumor cells and unmodified tumor cells both in vitro and in vivo we observed that the PA-STK ovarian tumor cells were sensitive to -irradiation, completely abolishing their ability to induce bystander killing of unmodified tumor cells. In contrast, TK-modified human and mouse mesothelioma cells were found to retain their in vitro and in vivo bystander killing effect after -irradiation. Characterisation of tumor cell death showed that PA-STK cells underwent pyknosis (necrosis) after -irradiation. These results suggest that PA-STK cells are not suitable for clinical application of suicide gene therapy of cancer, as lethal -irradiation (100Gy) interferes with their bystander killing activity. However, the human mesothelioma cell line CRL-5830-TK retained its bystander killing potential after exposure to similarly lethal -irradiation (100Gy). CRL-5830 may therefore be a suitable vehicle for HSV-TK suicide gene therapy. This study highlights the diversity among tumor cell lines and the careful considerations needed to find the optimal tumor cell line for this type of whole cell tumour vaccination.
Biography: My research activity has been centered on the study of nuclear receptors and transcription factors in hormone-dependent tumors. In my Master’s degree I studied the effects of dietary factors in breast cancer initiation and progression in animal models, activity that I complemented teaching to second year medical students at the Autonomous University of Barcelona. Later, during my PhD at the Vall-Hebron Research
Institute of Barcelona, my work focused on understanding the non-genomic actions of Estrogen Receptor (ER) in Prostate cancer. The main interest during my post-doctoral research at Cambridge University (UK) was to understand the mechanisms of resistance for endocrine treatment in luminal breast tumors, which led to four significant publications (i.e. Nature, Nature Genetics). In late 2011 I became young group leader at University of Oslo. Over the past six years, I have built a team and I have developed a research programin functional genomics and proteomics of breast, colon and endometrial cancers. In summer of 2019 I will lead a cancer genomics group at the Department of Biomedical Sciencies (Faculty of Medicine; University of Barcelona). My past research group has: (1) a proven track record with a total of 21 papers, (2) successfully established national and international research collaborations and (3) attracted significant external funding from several sources (Norwegian and Spanish funding bodies). In addition, I have trained several PhD students and undergraduate students. The scientific and
educational supervision was complemented with teaching at the University of Oslo.
Abstract: HER2 is overexpressed in a significant number of endometrial cancer (EC) tumors. Yet, the prognostic and therapeutic implications of HER2 expression have not been clearly elucidated. Here we identify that FOXA1 expression stratifies tumors with HER2-high expression into two subgroups that significantly and independently associates with prognosis. Our study suggests that HER2-high tumors with low levels of FOXA1 possess innate resistance against HER therapies. The comparison of genes differentially expressed between FOXA1-high vs. FOXA1-low within the HER2-high subgroup of EC patients revealed an enrichment of a gene signature that have been found to be associated with response to the anti-EGFR drug Gefitinib. In EC cells, FOXA1 binds towards a significant number of these genes associated with response, and the increased expression of FOXA1 attenuates the expression of these genes by recruiting polycomb-associated proteins to FOXA1 binding sites. Moreover, the ectopic expression of FOXA1 results in a full response to anti-EGFR/HER2 therapies. This result suggests that in HER2-high tumors, FOXA1 represses the expression of genes key for EGFR-HER2 signaling and might explain why women with high FOXA1 and HER2 overexpressing EC show improved outcome. Moreover, these results might explain why women with HER2-high EC in general respond poorly to current HER2-directed therapies.
Biography: Dr. Cristina-Crenguta Albu is an Associate Professor of Department of Medical Genetics at Bucharest, "Carol Davila" University of Medicine and Pharmacy, Romania and General Manager of Bucharest "Alco San" Medical Clinic, Romania.
She received her M.D. degree in Medicine from Bucharest, "Carol Davila" University of Medicine and Pharmacy, Romania, in 1991 and her Ph.D. degree in Medicine (Ophthalmology) from Bucharest "Carol Davila" University of Medicine and Pharmacy, Romania in 2001.
Dr. Cristina-Crenguta Albu is a member of several scientific societies including International Society for Genetic Eye Disease & Retinoblastoma, American Society of Human Genetics, European Society of Human Genetics, Pan-American Association of Ophthalmology, American Academy of Ophthalmology, European Society of Pediatric Ophthalmology.
She serves on the editorial board of International Journal of Medical and Clinical Research, Journal of Genetics and Genomes, Genetics and Genetic Disorders, Journal of Chemical Biology & Pharmaceutical Chemistry, International Gazette Of Research and ePublishers.
Dr. Cristina-Crenguta Albu is author and co-author over 200 publications (medical textbooks, articles and studies published in medical journals and conferences) in the fields of prenatal genetics diagnosis and ophthalmology.
Her Research Interest is focused on medical genetics, prenatal diagnosis, ophthalmogenetics and oculo-orbitar ultrasound examination.
Abstract: Retinoblastoma is a malignant eye tumor of early childhood, typically before the age of 5. This form of eye cancer it develops rapidly from the immature cells of a retina.
The incidence of retinoblastoma is one case of retinoblastoma per 18,000 - 30,000 live births worldwide, in developed nations.
Retinoblastoma is the most common malignant cancer of the eye in children.
Retinoblastoma occurs in heritable (25-30%) and nonheritable (70–75%) forms.
In 25-30% of cases, the mutation of the RB1 gene have been inherited from an affected parent (heritable form of Retinoblastoma) and in 70–75% of cases the mutation of the RB1 gene occurred in utero during early embryogenesis or before conception (nonheritable form of Retinoblastoma).
Material and Metods:
I present a very special case of heritable form of retinoblastoma, in a family with a structural abnormality of a chromosome 13: 13q deletion syndrome (13q del).
Results and conclusion:
The presence of positive family history is suggestive for the heritable form of Retinoblastoma.
Abstract: Althoughthe genetic alteration of CUB and Sushi multiple domains 1 (CSMD1) have been known to be associated with poor prognosis in several cancers, there is a lack of clinical relevance in head and neck cancer. The aim of this study was to offer the insight into clinical significance of CSMD1 utilizing a multimodal approach that leverages publicly available independent genome wide expression datasets.CSMD1-related genes were found and were analyzed to examine the clinical significance of CSMD1 inactivation in HNSCC cohort of publicly available database. We analyzed the frequency of somatic mutation, clinicopathologic characteristics, the association with immunotherapy-related gene signature and the pathway of gene signature.We found 363 CSMD1-related genes.The prognosis of the CSMD1-inactivatedsubgroup was poor. A FBXW7, HLA-A, MED1, NOTCH2, NOTCH3, and TP53had higher mutation rates in the CSMD1-inactivated subgroups. The Interferon-gamma score and immune signature score were elevated in CSMD1-inactivated subgroups. We identified CSMD1-related several pathways,such as phosphatidylinositol signaling system and inositol phosphate metabolism.Our study suggests that CSMD1-related gene signatures using three large and independent datasets are associated with the prognosis of HNSCC patients.
Abstract: Cell-free DNA extracted from plasma or other body fluids could potentially replace invasive biopsies. It could be used to assess tumor genetic and epigenetic characteristics and has significant potential role for cancer screening, prognosis and monitoring of the efficacy of anticancer therapies. Despite the extensive clinical utility of cfDNA, there are some challenges, and difficulties in its extraction and subsequently, its usage. CfDNA is frequently found in plasma at very low concentration and exists in fragmented condition. In addition, circulating tumor DNA (ctDNA) with genetic and epigenetic alterations can be mixed by normal free DNA, released in the bloodstream (1.0% of total cfDNA). Besides, tumors, themselves are a mixture of different cancer cell clones (inter-tumoral heterogeneity) which could lead to more complexity. Thus, isolation, quantification and evaluation of cfDNA is not a straightforward task and it requires a sensitive and reliable validation workflow. In this study, we designed and performed several simple experiments to perform this task.
Material and methods: The abilities of the common QIAamp DNA Blood Mini Kit method to extract cfDNA were assessed by several approaches including purification of endogenous cfDNA and exogenous spike-in control material to plasma prior to extraction followed by quantitative-PCR.
Results: By using this kit, nearly 27% (DAZ, 380 bp) to 35% (DYS221, 173 bp) cfDNA was recovered and there was a higher recovery for smaller size cfDNA (DYS221, 173 bp) in compare to larger sizes (DAZ, 380 bp).
Conclusion: The suggested simple laboratory methods could be used to assess the efficiency of any cfDNA isolation method.
Clinical Trials In Oncology
Biography: Professor Dr. Sorush Niknamian (Professor Sir Sorush Niknamian). Ph.D in Cellular and Molecular Biology from the University of Cambridge. He is a CSci (Chartered Scientist), RSciTech (Registered Science Technician), RSci (Registered Scientist) and Science Council, United Kingdom and Indiana Cancer Consortium (ICC) certified. He is the Board member of Weston A. Price Foundation in Washington, United States, Member of American Association for Cancer Research (AACR), Ambassador of European Association for Cancer Research (EACR), Member of Federal Health Professionals in the United States Marine Forces, Army Forces and Military Medicine, Registered Researcher in the U.S. Government's System for Award Management (NAS) and certified member of Royal Society of Biology (MRSB) and the Royal Society of the Great Britain. He has been published 27 books in medical and biological sciences including cancer prevention and treatment. He has published more than 25 research articles in international high impact journals in many fields of medicine. He has been working on cancer treatment, Cause and Prevention alongside Professor Thomas N. Seyfried, Professor Stephanie Seneff, Professor Domonic D’Agostino and Miriam Kalamian. He has hypothesized cancer as an evolutionary metabolic disease (Disorder) and introduced a new protocol in the treatment of cancer. He is a Professional Reviewer at National Institute for Health Research (NIHR), United Kingdom, Editor of the Publishing Research Group, American Society of Clinical Oncology (ASCO), Member of peer review corps at Journal of Clinical Oncology (JCO), JCO Clinical Cancer Informatics, JCO Precision Oncology, Journal of Oncology Practice, Dove Medical Press (Adolescent Health, Medicine and Therapeutics Journal), Dove Medical Press. (Biologics: Targets and Therapy Journal) and Dove Medical Press (Cancer Management and Research) and etc. He is the Guest editor of Nature Medicine Journal and the editorial Board Member of Global Access Publishers (Global Journal of Neurology). He is a nominee of Edison Award 2019.
Abstract: Background: The aim of this research is to figure out the effectiveness of the Sorush Cancer Treatment Protocol (SCTP) which is based on the Evolutionary Metabolic Hypothesis of Cancer (EMHC) and introducing the Specific Ketogenic Diet (SKD) plus Intravenous Ozone Therapy (IOT) in Phase (1) on 54 cancer patients, and combination of Hyperbaric Oxygen Therapy with vitamin/mineral and herbal supplementation beside the SKD and IOT in Phase (2) of this research on the remaining 31 cancer patients.
Introduction: Cancer based on the introduction of EMHC by Dr. Somayeh Zaminpira and Dr. Sorush Niknamian in 2017, is an evolutionary metabolic disease and through the incline of the Reactive Oxygen Species (ROS) and the Butterfly Effect in normal eukaryotic cells, the mitochondria become damaged or shut down. Cancer cells are primitive eukaryotic cells which have existed since around 1.5 billion years ago before the entrance of mitochondrion as endosymbiont.
Materials and Methods: Based on the researches from 1928-2016 and the experimentation of cancer treatments and protocols on cancer patients, we have reached a treatment and decided to test it on 54 voluntary cancer patients in the first stage of their disease. In this treatment we used a 5-day water fasting state, the Specific Ketogenic Diet (SKD) designed by ourselves and Intravenous Ozone Therapy (IOT) in the duration of 90 days (Phase 1) and another 90 days (Phase 2) with the entrance of Hyperbaric Oxygen Therapy (HBO2T) and several supplements which have been effective in previous studies on cancer patients. We have used the measurement of saliva PH, the MRI device and statistical methods to test the shrinkage of the tumors.
Results: After Phase (1) of this research on 54 patients the average percentage decrease in the tumors was 58% and after Phase (2) on 31 remaining cancer patients the average percentage decrease in the tumors was 98.8%. The average saliva PH in the fasting state of the cancer patients improved from acidic to alkaline as well.
Conclusion: in conclusion, we have reached an effective cancer treatment based on SCTP by the usage of SKD, IOT, HBO2T and several supplements. There was an obvious improvement of cancer tumor decrease, lifestyle, saliva PH and we did not observe any side effects or cachexia in any of the patients.
KEYWORDS: EMHC Hypothesis; SKD; IOT; ROS; HBO2T; SCTP
Abstract: Aims. CD4+FOXP3+ T cells and Pten expression were previously implicated in the
development of some cancers. We have now investigated the potential role of Pten
and CD4+FOXP3+ T cells in prognosis from endometrial cancer.
Methods. Tissue samples and clinical data were collected from 200 patients with
endometrial cancer and 100 control patients with benign uterine diseases. The
expressions of Pten and CD4+FOXP3+ T cells were quantified by
immunohistochemistry and immunofluorescence. After surgery, all patients were
followed up for an average of years. Surgical effects were evaluated based on the
patients’ symptoms and signs. A two-sided P value < 0.05 was considered significant.
Results. Pten diminished and CD4+FOXP3+ T cells significantly accumulated in the
progression of endometial cancer, in comparison to control tissues. Moreover, Pten
expression is negatively correlated with CD4+FOXP3+ T cells. Importantly, Pten and
CD4+FOXP3+ T cells were correlated with clinical characteristics, including tumor
stage, differentiation and associated with patients’ disease-free survival.
Conclusions. There are limited researches between the expressions of Pten and
CD4+FOXP3+ T cells in patients with endometrial cancer. This data suggested the
expressions of Pten and CD4+FOXP3+ T cells may possibility biomarkers of diagnosis
and predictive in endometrial cancer.
Abstract: Identifying diagnostic and prognostic biomarkers is crucial for improved guidance of the treatment of renal cell carcinoma (RCC). Amyloid β precursor like protein 2 (APLP2) has been determined to serve an important role in the progression of a number of cancer types. However, the expression and significance of APLP2 in RCC remains unknown. In the present study, it was determined that the expression of APLP2 protein (n=10) and mRNA (n=8) expression was significantly decreased in clear cell RCC (CCRCC) tissues compared with that in matched normal renal tissues. The expression level of APLP2 was significantly associated with high Fuhrman grade, high pT stage, and presence of distant metastasis and lymph node metastasis (P<0.05). Multivariate analysis demonstrated that the expression of APLP2 was a significant independent predictor of disease specific survival in renal cell carcinoma (P=0.026). Notably, APLP2 expression was significantly associated with disease specific survival (P<0.001). APLP2 may be used to potentially predict patient prognosis, and to guide clinical diagnosis and treatment in CCRCC.
Abstract: Osteosarcoma (OS) is one of the most prevalent malignant cancers with lower survival and poor overall prognosis
mainly in children and adolescents. Identifying the molecular mechanisms and OS stem cells (OSCs) as new concepts
involved in disease pathogenesis and progression may potentially lead to new therapeutic targets. Therefore,
therapeutic targeting of OSCs can be one of the most important and effective strategies for the treatment of OS. This
review describes the new molecular targets of OS as well as novel therapeutic approaches in the design of future
investigations and treatment.
Abstract: Introduction: The aim of this study was to investigate the expression levels
of microRNA-182 and microRNA-183 and their association with clinicopathological
features in patients with osteosarcoma.
Material and methods: Total RNA was purified from samples and noncancerous
bone tissues and then quantitative real-time polymerase chain reaction
was applied to evaluate the expression levels of microRNAs, and their
relationship with clinicopathological features and survival in osteosarcoma
Results: Our findings showed that expression of MiR-182 was clearly lower
in osteosarcoma bone tissue (mean ± SD: 2.84 ±.07) compared with noncancerous
bone tissues (6.23 ±1.72, p = 0.004). On the other hand, lower
expression of MiR-183 was seen in osteosarcoma bone tissue (1.43 ±0.59)
when compared with normal tissues (4.36 ±2.47, p = 0.036). Decreased
expression of MiR-182 was clearly correlated with advanced clinical stage
(p = 0.001), metastasis or recurrence (p = 0.024), and large tumor size
(p = 0.032). Decreased expression of MiR-183 was associated with advanced
TNM stage (p = 0.004), and metastasis or recurrence (p = 0.002). A multivariate
Cox proportional hazards model revealed that low expression of
MiR-182 and MiR-183 (p = 0.02; p = 0.016), TNM stage (p = 0.04), and
metastasis or recurrence (p = 0.03) were significantly associated with poor
survival as independent prognostic factors.
Conclusions: These findings suggest that MiR-182 and MiR-183 may be associated
with progression and metastasis of osteosarcoma.
Biography: Maria Alexandra Brito is Associate Professor with Tenure at the Faculty of
Pharmacy, University of Lisbon. She is the head of the Neurovascular
Laboratory, within the Neuron Glia Biology in Health and Disease Group, of
the Research Institute for Medicines (iMed.ULisboa), at the same Faculty. She
has studied the neurovascular alterations in brain pathologies, including primary
and metastatic brain tumours, dissecting the signalling pathways and identifying
biomarkers and targets for modulation. Her work has been presented in reputed
scientific meetings and published in high impact journals, and has been awarded
several grants and prizes.
Abstract: Breast cancer (BC) is the most frequent type of cancer in women. With the enormous advances in
BC treatment the major concern shifted to metastasis. BC brain metastases occur in 15-25% of BC
patients and the 1-year survival is only 20%. To these numbers account the fact that malignant cells’
transposition of the blood-brain barrier endothelium towards the brain and the players involved in the
target organ colonization are poorly understood, together with the fact that early biomarkers of brain
metastasization remain to be established. Our current studies directed to the clarification of the brain
metastatic process and to the identification of precocious biomarkers in peripheral circulation will be
presented. Moreover, specific targets for modulation will be pinpointed and risk identification relying on
liquid biopsies will be pointed out.
Cancer diagnosis and Treatment
Abstract: Although many diagnostic methods/criteria of non-small cell lung cancer (NSCLC) have been developed, early diagnosis of NSCLC is still challenging and far from satisfactory. Early detection of NSCLC is very critical because if it can be detected at the earlier stage, most of cases can be cured via surgical resection of the tumor. Among various metabolites in NSCLC, we have discovered the changes in 15-lipoxygenases (15-LOXs) and their metabolites in the very early stage of lung tumorigenesis. Among them, 15(S)-hydroxy-eicosatetraenoic acid (15S-HETE) appears to be most promising. The data from high-risk population suggests that 15S-HETE is valuable for screening smoking population for early detection of NSCLC. (This study was supported by a grant from the Research Grants Council of the Hong Kong SAR, No: CUHK462613, and the National Natural Science Foundation of China National, No: 81472742. Contributors: Ming-Yue Li, Yi Liu, Ho RL, Leung BC, Fanny WS Ko, Bin Wu, Xiang Long, Jing Du, Jun Wu, Calvin SH Ng, Innes YP Wan, Tony SK Mok, David SC Hui, Malcolm J Underwood).
Biography: Professor of Radiology Faculty of Medicine Cairo University Cairo Egypt
Consultant Radiologist Dr .Erfan and Bagedo General Hospital
Member of the Europian Society of Radiology.
Member of the Radiological Society of North America.
Member of the Radiological Society of Saudi Arabia .
Member of the Egyptian Society of Radiology.
Abstract: Purpose: To determine the accuracy of Bi-parametric 3 Tesla MRI versus the usual Multi-parametric technique in cases of transitional zone (TZ) prostate cancer, based on Prostate Imaging Reporting and Data System (PI-RADS) version 2 scores.
Methods and Materials: A total of 23 men underwent Multi-parametric( mp)- 3Tesla MRI ,revealing suspicious lesions in the transitional zones. . Of the included patients, , 92 % had TRUS-biopsy . Two radiologists separately assessed the mp-MRI examination (T2-weighted [T2W] imaging, diffusion-weighted imaging [DWI], apparent diffusion coefficient map [ADC-map] and dynamic contrast-enhanced imaging [DCE]). , The Bi-parametric (bp)-MRI version (T2W imaging, DWI, and ADC-map) was evaluated.PI-RADS) version 2 scoring system was applied and results were correlated with the hist pathological results.
Results: Suspicious TZ lesions were more observed in the mp-MRI group than in the b-MRI group, although this difference was not statistically significant (; p=0.122). The overall detection rates of clinically significant cancers were not statistically significantly different between the two groups. In the 23 patients who had suspicious TZ lesions on MRI, the overall prostate cancer detection rate was (64.5%) in the mp-MRI group and (62.3%) in the b-MRI group (p=0.94). We compared the diagnostic accuracy using the sensitivity and specificity between mp-MRI and b-MRI. There were no statistical differences between the two.p values for sensitivity , specificity, PPV and NPV of both groups were (0.88, 0.23, 0.829 and 0.838 ) respectivley.
Conclusion: The comparable accuracy of b-MRI technique could encourage its application in cases of TZ cancer lesions prior to biopsy.
Ultrasonic elastography can be used to assess the mechanical properties of soft tissue such as elasticity and thus the presence of pathology. Shear wave elastography (SWE) is a quantitative type of this technology. This study aimed to investigate the validity and operator’s reliability of three SWE systems in a phantom study.
Materials and Methods:
Two observers undertook a total of 2080 measurements of a phantom across three SWE systems; the GE LOGIQ E9 (GE-L), SuperSonic Imagine Aixplorer (SSI) and Siemens Acuson S2000 (SA). Inter-observer variation was assessed using box-plots and coefficient of variation. Validity and accuracy were assessed by calculating mean difference. Agreement was assessed by plotting mean difference and limits of agreement (LOA). Intraclass correlation coefficients were used to evaluate intra- and inter-observer, as well as inter-system reliability.
Measured elasticity decreased in softer inclusions as diameter increased, but increased for harder inclusions. Great biases between measured and actual elasticities were observed across all systems; though validity and accuracy were higher for softer inclusions. A pooled CV of 0.011-0.216 m/s across systems indicated low variability and high reproducibility. The LOAs were wide compared to the mean differences: GE-L: 0.509 [95 LOA: -2.43, 3.45]; SSI: 0.842 [95%LOA: -2.20, 3.88]; SA: -0.136 [95%LOA: -3.54, 3.26]. Inter-observer reliability was ‘almost perfect’ for all systems; ICC: 0.975- 0.994; 95%CI [0.916- 0.998]. Intra-observer reliability was 'almost perfect' for all inclusions and systems, ICC= 0.861-0.999; 95%CI [0.598-0.999] bar one inclusion per observer for the SA; ICC= 0.476-0.528; 95%CI [0.157-0.979], which was 'moderate' reliability. Inter-system reliability was higher across all systems for the experienced observer but varied between systems from 'poor' to 'almost perfect'.
The accuracy of SWE readings are influenced by ROI size, inclusion stiffness and the system employed; thus, standardization of methodology and technology is required. Operator experience may improve inter-system reliability but showed little influence on intra- and inter-observer reliability.
Biography: Dr. Jaap Dronkers took Master’s degrees in Education and Health Sciences. When working in the Gelderse Vallei Hospital, he investigated the role of physical fitness in elderly patients scheduled for major abdominal surgery and completed his doctorate on this subject in 2013. As senior researcher in the research group Innovation of Human Movement Care at the University of Applied Sciences in Utrecht, he has extended his studies and expertise to include abdominal and thoracic oncological surgery and the physical fitness (or lack thereof) of patients during hospital admission. At the University of Applied Sciences, he coordinates the Master’s program Physiotherapy.
Abstract: Muscle function is an important determinant of physical fitness and is not only needed for movement and locomotion. Muscle function encompasses muscle mass, strength and use. Muscle mass has an important role as protein store. In the case of impaired food intake or undernutrition, the body uses muscle proteins to cope with disease and inflammatory processes and treatment, in particular surgery. This is why patients lose muscle mass during illness and treatment. Muscle strength is also lost during illness. Cancer and its treatment (surgery and chemotherapy) cause an acute and rapid decrease in both muscle mass and strength, and especially in older patients, who often fail to regain lost muscle mass and strength, leading to long-lasting and sometimes permanent loss of functional mobility. Muscle is also a secretory organ, and muscle use leads to the release of myokines, which have important metabolic and anti-inflammatory actions. Physical activity has beneficial effects on health, improving immune function and aiding recovery from medical treatment.
Cancer patients need to be as physically fit as possible in order to cope with the challenge of having the disease and undergoing treatment. Patients should be encouraged to use the preoperative period to improve their physical condition before treatment starts: ‘Better in’ means ‘better out’. Being physically active and having muscle mass and strength reduces the risk of complications and death. And appropriate muscle use after cancer treatment may reduce the risk of cancer recurrence.
Trends in Cancer Research and Therapies
Biography: Celine Cano is Assistant Professor (Reader) in Medicinal Chemistry at Newcastle University. She graduated from the University of Poitiers, receiving her Ph.D. in 2004 for her work on the synthesis of biomolecules by 1,3-dipolar cycloadditions with carbohydrates. In 2004, she carried out post-doctoral work in the group of Professor John A. Joule at the University of Manchester working on the synthesis of analogues of cofactors of oxomolybdoenzymes. In 2005 she joined the Northern Institute for Cancer Research at Newcastle University as a research fellow, working on the synthesis of inhibitors of the DNA-dependent protein kinase (DNA-PK). She was appointed to a lectureship in Medicinal Chemistry at Newcastle University in 2008 and has since played a key role in helping to establish Newcastle as an internationally recognised centre for anti-cancer drug discovery. Celine was awarded the Elsevier Reaxys 2016 Prize for Medicinal Chemistry in recognition of her research into anticancer drug discovery. She is the academic lead for the Medicinal Chemistry and Chemical Biology Group within the School of Natural and Environmental Sciences.
Abstract: The cellular response to DNA double-strand break (DSB) formation is an essential component of normal cell survival, following exposure to DNA-damaging chemicals (e.g. cisplatin and doxorubicin) and ionising radiation . The serine/threonine kinase DNA-dependent protein kinase (DNA-PK) is a member of the phosphatidylinositol (PI) 3-kinase related kinase (PIKK) family of enzymes, and plays an important role in DNA DSB repair via the non-homologous end-joining (NHEJ) pathway . DNA-PK inhibitors may, therefore, be useful as agents to improve the activity of radio- and chemo-therapy in the treatment of cancer . Identification of the lead benzo[h]chromen-4-one DNA-PK inhibitor NU7026 (IC50 = 0.23 uM), guided the subsequent development of the potent and selective ATP-competitive chromenone NU7441 (DNA-PK IC50 = 30 nM) . Although proof-of-principle studies with NU7441 confirmed promising activity in vitro as a chemo- and radio-potentiator in a range of human tumour cell lines , further biological studies with NU7441 were hampered by sub-optimal pharmaceutical properties.In collaboration with AstraZeneca Pharmaceuticals, structure-activity relationship studies for DNA-PK inhibition by chromenone-derivatives were conducted in conjunction with homology modelling. This approach predicted several positions on the pendant dibenzothiophen-4-yl substituent of NU7441 as tolerant to substitution, without detriment to DNA-PK inhibitory activity. We will describe the rational design and syntheses of analogues that optimised the physicochemical and pharmacokinetic properties of NU7441. These studies resulted in the identification of compounds that combined potent DNA-PK inhibition with excellent aqueous solubility (20-40 mg/mL as acid salts), without compromising cellular activity. Prominent amongst these derivatives is KU-0060648 (DNA-PK IC50 = 8.6 nM), which exhibits 20-1000 fold selectivity for DNA-PK over related PIKK enzymes and PI3K family members. The discovery and further development of KU-0060648 and analogues will be described, including in vivo efficacy and combination studies [6-8].
Biography: Kumari Anuja has completed her M.Sc from KIIT University, School of Biotechnology, Bhubaneswar, India. She is currently working as Research scholar in KIIT University. Her research topic is role cancer stem cells in therapeutic radio-resistant. She has also published her previous research in reputed journals
Abstract: Radiotherapy is an integral part of current treatment modality which is confined to use of Ionizing Radiation (IR) for colorectal cancer. IR behaves as mutagen and induces double stand break which affects the genome integrity leading to cell apoptosis. Existence of cancer stem-like cells (CSCs) population showing resistance to IR may contribute to treatment failure and tumor relapse. Thus, characterization of effect of IR in colorectal cancer may serve to elucidate possible mechanisms associated with it. In this study, colorectal cancer cells (HCT116 and HCT-15) and derived clonospheres were irradiated with different doses and based on cell survival assay and cell cycle analysis dose was optimized. Presence of cancer stem- like cells population was characterized by CD44 expression. The extent of DNA damage response (DDR) and repair was elucidated by γH2AX foci formation with different time-points post-irradiation, and further confirmed by COMET assay. Expression level of DNA damage repair proteins ATM, ERCC1 was checked with western blotting and mRNA fold change post treatment. It was observed that percentage cell death was less in clonospheres post irradiation and clonospheres also exhibited less γH2AX foci, decreased olive tail moment and increased ERCC1 expression than its parental counterpart which corresponds to efficient DDR in clonospheres post irradiation. This study highlighted the presence of CSC phenotype in clonospheres having increased DNA repair capacity and enhanced expression of ERCC1 in clonospheres may contribute in radioresistance property of CSCs and therapeutic treatment failure and recurrence.
Abstract: MicroRNAs are pivotal regulators for RNA silencing and post-transcriptional regulation of gene expression under physiological as well as pathological conditions. MicroRNAs can be detected in tissues and in most biologic fluids including serum, plasma and urines. Secreted microRNAs are either incorporated into micro-vesicles or circulate bound to proteins. In both cases microRNAs are protected from RNase degradation so that they may remain intact for long periods of time. Therefore they might represent potential new biomarkers.
We analysed expression of 800 miRNA’s using nCounter Nanostring technology in cancer cell lines, formalin fixed paraffin embedded tissues and plasma from cancer patients. Potential clinical applications of microRNA detection for cancer patients’ management will be discussed.
Abstract: The Auger effect is a physical phenomenon in which the filling of an inner-shell vacancy of an atom is accompanied by the emission of an electron from the same atom. An Auger electron is estimated to have a travel distance around 2-100 μm, within which an energy up to 106 gray is released. Therefore, if Auger effect can be induced in cancer cell DNA, it could mediate immense damage concentrated in cancer genome, providing a potential approach for cancer therapy. Auger effect can be induced by radioactive isotope itself, like 125I, or monoenergetic X-Ray in combination with specific heavy atom. Conventionally, monoenergetic X-Ray can be produced only in a synchrotron radiation accelerator, which hinders its application in medical use.
Here, our study showed that a novel design of X-Ray tube allowing electron beams to pass through the target metal can generate monoenergetic X-ray efficiently. This design substantially minimizes the size of X-Ray generator to be portable, and can generate 3-fold higher X-Ray production than traditional X-ray tube under the same voltage and current-exposure time. The monoenergetic X-Ray generated by the novel design (denominated as NanoRay hereafter) contains >20% of K-characteristic photon, up to 29-fold higher than traditional X-Ray in the same energy range.
For anti-cancer analysis, 14 and 33 keV NanoRays were combined with Thymidine analogues BrdU and IdU, respectively, in cancer cell treatment. The results showed that while single treatments showed low cytotoxicity, the combination of Nanorays with BrdU or IdU induced significant cancer cell death synergistically in vitro. In contrast, combined treatments of conventional radiation with BrdU or IdU did not show any synergistic effect. In vivo tumor treatment combining 33 keV NanoRay and IdU showed a tumor reduction rate up to 80% as compared to Nanoray alone. Likewise, combination of conventional radiation with IdU showed no synergistic anti-tumor effect. DNA damage analysis found that NanoRay produced 2-fold more double-strand breaks (DSBs) in cancer cells incorporating BrdU or IdU than control cells, validating the Auger effect induced and applied in cancer genome damage.
In summary, the current study presents that NanoRay, a new generation of medical X-Ray with highly specific monoenergetic spectrum, can be generated from a transmission tube within a portable apparatus. When NanoRay is applied to cancer DNA incorporating specific heavy atoms, such as BrdU or IdU, it induced significantly more pronounced DNA DSBs and cell death through Auger effect, thus lowering the dose necessary for corresponding anti-tumor effect induced by conventional radiation. NanoRay serves as a novel medical X-Ray source with low dose, low cost, and high efficiency, holding great promise in future cancer therapy.
Abstract: Background: ATM is a critical first responder to DNA damage in the cell, but despite being one of the most mutated genes in lung cancer, the prognostic and therapeutic value of ATM loss has yet to be determined. Unlike the therapeutic biomarkers EGFR and ALK, there are no predictable mutation hot spots in the ATM gene that are actionable in a clinical setting. Systemic ATM loss results in ataxia telangiectasia, characterized by compromised immunity, susceptibility to radiation, and predisposition to cancer formation. Our work over the last several years has sought to determine the implications of cancer-specific ATM loss in NSCLC and we have shown that loss of ATM protein expression and phenotype, or “ATMicity”, regardless of mechanism, yields important consequences for cancer patients at the cellular level.
Clinical Implications: We have used quantitative immunohistochemistry to accurately determine cancer-specific ATM protein levels in resected tissue from a cohort of 165 stage I and II NSCLC patients. ATM protein was quantified in tumour and stromal components of the resected tissue and the tumour levels were normalized to stromal levels to define an ATM expression index (ATM-EI). Approximately 22% of patients were found to have low ATM-EI and had both poorer 5-year progression free survival (PFS) and poorer overall survival (OS) than patients with high ATM-EI.
Therapeutic Implications: In our cohort, a subset had received adjuvant chemotherapy following surgical resection, typically comprised of a platin/vinca alkaloid doublet. Patients with high ATM-EI saw no benefit from adjuvant treatment from a PFS or OS perspective, however those with low ATM-EI did see increased survival benefit. We investigated these findings in an in vitro setting and observed that NSCLC cells with endogenous ATM loss, or cells in which ATM had been knocked out by CRISPR had increased sensitivity to cisplatin treatment. These cells also have high sensitivity to PARP inhibition, and we have shown that a combination of cisplatin and low-dose PARP inhibitor is particularly lethal to ATMic cells.
Determining ATMicity: We have shown that tumour ATM protein expression is predictive of survival, however we have been seeking to validate ATM loss by other means. While no clinically relevant hot spot mutations have been described for ATM, we have demonstrated in silico that ATM mutations correlate with an increased mutation burden in lung and other cancer cell lines. We have also performed RNA-seq and Oncofinder analysis on patient samples to determine the mRNA expression of ATM and ATM-related pathway activation.
Conclusions: Our cumulative work suggests that ATM is an important predictor of survival for early-stage NSCLC and may be a potential indicator of therapeutic response to low-dose platins and PARP inhibitors. We are exploring methods to best determine ATMicity, by protein expression, mRNA expression and pathway activation, or by mutation and mutation burden. Although unlikely to displace EGFR or ALK as a dominant biomarker for targeted therapy in NSCLC, therapy based upon ATM status may provide benefit for those patients with no current actionable targets.
Biography: Che-Hung Shen is now an assistant investigator of National Institute of Cancer Research, National Health Research Institutes, Taiwan. He has completed his Ph.D. degree from National Taiwan University in 2008 and postdoctoral studies from Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard University in 2016. His research interest is focused on the molecular mechanisms of drug-resistant development in melanomas and colorectal cancers, and preclinical studies of the potential therapeutic targets.
Abstract: TRPM1, a transient receptor potential cation channel subfamily M member 1, is an important diagnostic and prognostic marker for primary cutaneous melanoma. The TRPM1 transcripts were negatively correlated with melanoma progression and had been suggested as a predictor of the risk of metastatic progression in melanoma. However, the protein function of TRPM1 in melanoma progression and the drug resistant development remains large unknown.
To study the function of TRPM1 in development of BRAFi resistant melanoma, we created dabrafenib resistant (DR) cell in two malignant BRAFV600E melanoma cell lines: A375 and Mel1617. We found the expression of TRPM1 was in a variety of melanoma cell lines and was up-regulated in the DR cells, compared to their drug sensitive counterpart. Next, we expressed TRPM1 shRNAs in DR cells and found that the knockdown of TRPM1 inhibited the cell growth of DR cells dramatically. Importantly, we found the expression of TRPM1 was downregulated in response to AUY922 (HSP90 inhibitor) treatment and TRPM1 physically associated with HSP90 complex. More, we found AUY922 triggered melanoma cell death. Finally, AUY922 inhibited the cell viability efficiently in both short-term and long-term treatment.
All together, we found TRPM1 protein is expressed in malignant melanoma cells and is essential for DR melanoma cell growth. AUY922 suppresses melanoma cell growth through down-regulating TRPM1 protein and triggering cell death.
Abstract: Skin cancer is a common and a locally destructive cancerous growth of the skin. There are three major types of skin cancer: (1) basal cell carcinoma, (2) squamous cell carcinoma and (3) melanoma, though more dangerous, than the first two varieties. Radiation therapy is very effective for treating skin cancer. The use of and search for drugs derived from plants have accelerated in recent years. Plants are rich in a wide variety of secondary metabolites, which have been found in vitro to have antimicrobial properties. The purpose of our study was to report the effectiveness of the combination of the Asteraceae plant extract and radiotherapy in the treatment of the skin cancer. The Asteraceae plant extract used in traditional medicine to treat skin burning in Tunisia. Here we investigate the radioprotector effect of the aqueous Asteraceae plant extract on a DNA plasmid (pGEM-3Zf-). Aqueous solutions of the samples were irradiated with 137Cs -rays at various doses in the presence or absence of Asteraceae plant extract. Gel electrophoresis analysis shows that the aqueous Asteraceae plant extract prevent radiation-induced DNA damage. Moreover, we found that the aqueous Asteraceae plant extract has antibacterial, antiviral and antifungal activity. These results encourage us to continue our study in vivo to show the effectiveness of the Asteraceae plant extract to enhance cancer cells death with γ-radiation and to selectively protect the normal tissues against the tumoricidal effects of radiation.
Biography: Amir Jafri is the founder of Immunicom and has served as Immunicom’s President and Chief Executive Officer since the company’s inception in 2013. Amir has over 25 years of experience in healthcare technology and devices. As a senior executive in Fortune 50 companies and his own startups, he has managed multi-billion-dollar products on a global basis and is highly experienced with global regulatory environments. He was COO at West Health Institute; VP/CTO, VP R&D and VP Operations at Cardinal Health managing products with $1B in annual revenue (NYSE: CAH); VP/General Manager Healthcare Division at Manpower Group, responsible for the healthcare practice nationwide across 35 locations (NYSE: MAN). Prior to joining Manpower, Amir founded various healthcare startups that were subsequently acquired. He has successfully managed global businesses and has a track record of success in every business he has led. Amir serves on the Board of various healthcare technology startup companies and non-profit organizations. Amir received his Bachelors of Science Degree from Houston Baptist University with a double major in Chemistry and Biology and a minor in History. He attended medical school at the University of Texas but pursued an entrepreneurial and corporate path.
Abstract: Tumor necrosis factor alpha (TNF-alpha) is a major cytokine involved in inflammation caused by bacterial infections and endotoxin release. TNF-alpha is cytotoxic to cancer cells and stimulates anti-cancer immune responses. Natural attenuation of TNF-alpha is through soluble TNF-receptors sTNF-Rs, sTNF-R1 and sTNF-R2 to control deleterious inflammatory responses. However, tumors shed sTNF-Rs as a survival mechanism to downregulate TNF-alpha anti-cancer immune responses and cancer patients have elevated levels of these receptors. Immunicom has developed a novel ligand affinity device to capture and remove these immune inhibitors from patients plasma in conjunction with apheresis in order to promote TNF activity as a cancer treatment. A preclinical study has been completed for treatment of canine cancers using Immunicom’s LW-02 device together with the Terumo Optia apheresis system. This treatment approach was demonstrated to be safe and effective with a best overall response rate of approximately 60%. Advancement to human clinical studies will be discussed.